HIV Infections, Marijuana
Conditions
Brief summary
The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.
Interventions
BEHAVIORALContingency Management - Cannabis
Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
Sponsors
The University of Texas Health Sciences Center, Houston
National Institute on Drug Abuse (NIDA)
The University of Texas Health Science Center at San Antonio
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name) * Self-report of cannabis use at least once per week in the 6-month period prior to consent * Provide a positive urine toxicology (UTOX) screen for cannabis * Not seeking treatment for cannabis use * Willing to stop using cannabis for 28 days and attend eight study visits over six weeks. * Ability and willingness to provide inform consent * English fluency
Exclusion criteria
* Currently receiving treatment for cannabis or other drug use disorder * Diagnosed or receiving treatment for a current major depressive or anxiety disorder * Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22) * Positive UTOX screen for opioids * Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sustained cannabis abstinence for 28-days | 28-days | Cannabis abstinence will be defined as sustained reduction in quantitative levels of 11-Nor-9-carboxy-Δ⁹-tetrahydrocannabinol (THCCOOH) for 28-days |
Countries
United States
Outcome results
None listed